Cell surface downregulation of NK cell ligands by patient-derived HIV-1 Vpu and Nef alleles

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue 1, 2016, Pages 1-10

  Galaski, Johanna ^a,b   Ahmad, Fareed ^c   Tibroni, Nadine ^a,b   Pujol, Francois M ^a,b   Müller, Birthe ^a,b   Schmidt, Reinhold E ^c   Fackler, Oliver T ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cell surface downregulation; HIV; Nef; NK cell ligands; Vpu

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BINDING PROTEIN; CD317 ANTIGEN; CD4 ANTIGEN; CELL SURFACE RECEPTOR; LIGAND; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL LIGAND; NEF PROTEIN; NK T B ANTIGEN; POLIOVIRUS RECEPTOR; UL16 BINDING PROTEIN; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VPU PROTEIN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; NATURAL KILLER CELL RECEPTOR; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ALLELE; AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; ARTICLE; BIOLOGICAL FUNCTIONS; CELL ACTIVATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MOLECULAR CLONING; NATURAL KILLER CELL; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; VIRUS PATHOGENESIS; BIOSYNTHESIS; DOWN REGULATION; GENETICS; HELA CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; TUMOR CELL LINE; VIROLOGY;

ALLELES; ANTIGENS, CD; ANTIGENS, CD4; CELL LINE, TUMOR; DOWN-REGULATION; GPI-LINKED PROTEINS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECEPTORS, NATURAL KILLER CELL; RECEPTORS, VIRUS; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84949599773     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000917     Document Type: Article

References (63)

1. Carlson JM, Schaefer M, Monaco DC, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science. 2014; 345:1254031.
2. McLaren PJ, Carrington M. The impact of host genetic variation on infection with HIV-1. Nat Immunol. 2015;16:577-583.
3. Kawashima Y, Pfafferott K, Frater J, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 2009;458:641-645.
4. Altfeld M, Gale M Jr. Innate immunity against HIV-1 infection. Nat Immunol. 2015;16:554-562.
5. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol. 2011;6:223-248.
6. Fenton-May AE, Dibben O, Emmerich T, et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology. 2013;10:146.
7. Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A. 2013;110:6626-6633.
8. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571-576.
9. Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat Immunol. 2015;16:563-570.
10. Abraham L, Fackler OT. HIV-1 Nef: a multifaceted modulator of T cell receptor signaling. Cell Commun Signal. 2012;10:39.
11. Wonderlich ER, Leonard JA, Collins KL. HIV immune evasion disruption of antigen presentation by the HIV Nef protein. Adv Virus Res. 2011;80:103-127.
12. Laguette N, Bregnard C, Benichou S, et al. Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. Mol Aspects Med. 2010;31:418-433.
13. Sandberg JK, Andersson SK, Bachle SM, et al. HIV-1 Vpu interference with innate cell-mediated immune mechanisms. Curr HIV Res. 2012;10: 327-333.
14. Roy N, Pacini G, Berlioz-Torrent C, et al. Mechanisms underlying HIV-1 Vpu-mediated viral egress. Front Microbiol. 2014;5:177.
15. Sauter D, Hotter D, Van Driessche B, et al. Differential regulation of NFkappaB- mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell Rep. 2015;10:586-599.
16. Willey RL, Maldarelli F, Martin MA, et al. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol. 1992;66:7193-7200.
17. Kerkau T, Bacik I, Bennink JR, et al. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med. 1997;185:1295-1305.
18. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature. 1991;350:508-511.
19. Schwartz O, Marechal V, Le Gall S, et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med. 1996;2:338-342.
20. Wildum S, Schindler M, Munch J, et al. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol. 2006;80: 8047-8059.
21. Michel N, Allespach I, Venzke S, et al. The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol. 2005; 15:714-723.
22. Haller C, Muller B, Fritz JV, et al. HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins. J Virol. 2014;88:14241-14257.
23. Kluge SF,Mack K, Iyer SS, et al. Nef proteins of Epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe. 2014;16:639-650.
24. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451:425-430.
25. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008;3:245-252.
26. Alvarez RA, Hamlin RE, Monroe A, et al. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol. 2014;88:6031-6046.
27. Arias JF, Heyer LN, von Bredow B, et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 2014;111:6425-6430.
28. Pham TN, Lukhele S, Hajjar F, et al. HIV Nef and Vpu protect HIVinfected CD4+ T cells from antibody-mediated cell lysis through downmodulation of CD4 and BST2. Retrovirology. 2014;11:15.
29. Veillette M, Desormeaux A, Medjahed H, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol. 2014;88:2633-2644.
30. Marras F, Bozzano F, Ascierto ML, et al. Of activating NK cell receptors in the control of chronic viral infections: the paradigm of HIV-1 and HCV. Front Immunol. 2014;5:305.
31. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol. 2013;31:163-194.
32. Ansari AW, Ahmad F, Meyer-Olson D, et al. Natural killer cell heterogeneity: cellular dysfunction and significance in HIV-1 immunopathogenesis. Cell Mol Life Sci. 2015;72:3037-3049.
33. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97:3146-3151.
34. Pegram HJ, Andrews DM, Smyth MJ, et al. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89:216-224.
35. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495-502.
36. Sowrirajan B, Barker E. The natural killer cell cytotoxic function is modulated by HIV-1 accessory proteins. Viruses. 2011;3:1091-1111.
37. Matusali G, Tchidjou HK, Pontrelli G, et al. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J. 2013;27:2440-2450.
38. Bolduan S, Reif T, Schindler M, et al. HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14, and 18 of the transmembrane domain. Virology. 2014;464-465:375-384.
39. Mlcochova P, Apolonia L, Kluge SF, et al. Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. Virology. 2015;482:72-78.
40. Bolduan S, Hubel P, Reif T, et al. HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A. Virology. 2013;440: 190-203.
41. Shah AH, Sowrirajan B, Davis ZB, et al. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe. 2010;8:397-409.
42. Cerboni C, Neri F, Casartelli N, et al. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol. 2007;88:242-250.
43. Kulpa DA, Collins KL. The emerging role of HLA-C in HIV-1 infection. Immunology. 2011;134:116-122.
44. Ahmad F, Hong HS, Jackel M, et al. High frequencies of polyfunctional CD8+ NK cells in chronic HIV-1 infection are associated with slower disease progression. J Virol. 2014;88:12397-12408.
45. Goffinet C, Allespach I, Homann S, et al. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe. 2009;5:285-297.
46. Mangeat B, Gers-Huber G, Lehmann M, et al. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta- TrCP2-dependent degradation. Plos Pathog. 2009;5:e1000574.
47. Margottin F, Bour SP, Durand H, et al. A novel human WD protein, hbeta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell. 1998;1: 565-574.
48. Vigan R, Neil SJ. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol. 2010;84:12958-12970.
49. McNatt MW, Zang T, Bieniasz PD. Vpu binds directly to tetherin and displaces it from nascent virions. Plos Pathog. 2013;9:e1003299.
50. Fritz JV, Tibroni N, Keppler OT, et al. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/tetherin. Virology. 2012;424:33-44.
51. Dube M, Roy BB, Guiot-Guillain P, et al. Suppression of tetherinrestricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol. 2009;83:4574-4590.
52. Estrabaud E, Le Rouzic E, Lopez-Verges S, et al. Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles. Plos Pathog. 2007;3:e104.
53. Geyer M, Fackler OT, Peterlin BM. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2001;2:580-585.
54. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995;270:988-991.
55. Kirchhoff F, Greenough TC, Brettler DB, et al. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med. 1995;332:228-232.
56. Chen J, Tibroni N, Sauter D, et al. Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma. PLoS One. 2015;10:e0120434.
57. Strebel K. HIV accessory proteins versus host restriction factors. Curr Opin Virol. 2013;3:692-699.
58. Jia X, Weber E, Tokarev A, et al. Structural basis of HIV-1 Vpumediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. Elife. 2014;3:e02362.
59. Mwimanzi P, Markle TJ, Martin E, et al. Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology. 2013;10:1.
60. Pickering S, Hue S, Kim EY, et al. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. Plos Pathog. 2014;10:e1003895.
61. Leonard JA, Filzen T, Carter CC, et al. HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements. J Virol. 2011; 85:6867-6881.
62. Schaefer MR, Wonderlich ER, Roeth JF, et al. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. Plos Pathog. 2008;4:e1000131.
63. Carl S, Greenough TC, Krumbiegel M, et al. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol. 2001;75:3657-3665.